1996至2030年美国胃肠道恶性肿瘤医疗支出的趋势与预测
该研究基于健康测量与评估研究所的经济数据和全球疾病负担研究的患病率数据,采用Joinpoint回归和自回归整合移动平均模型,分析1996至2016年美国胃肠道恶性肿瘤医疗支出趋势并预测至2030年。2016年总支出主要来自结直肠癌和胰腺癌,且以住院服务为主;尽管总支出增加,胰腺癌、胆囊/胆道癌和胃癌的每患者支出近年下降。
要点
- 2008至2016年胰腺癌每患者支出年度百分比变化为-1.4%,2010至2016年胆囊/胆道癌为-4.3%,2011至2016年胃癌为-4.4%。
核心结论
- 美国胃肠道恶性肿瘤总支出巨大且预计将增加,支出主要由结直肠癌的住院服务驱动,但不同癌种的每患者支出趋势各异。
研究设计与样本
- 研究使用健康测量与评估研究所为疾病支出项目开发的经济数据(经通胀调整),结合全球疾病负担研究的美国年龄标化患病率,采用Joinpoint回归估计患病率调整后的时间趋势(以年度百分比变化及95%置信区间表示),并使用自回归整合移动平均模型预测至2030年。
主要发现
- 尽管总支出增加,近年每患者支出在胰腺癌(2008-2016年APC -1.4%;95% CI,-2.2%至-0.7%)、胆囊/胆道癌(2010-2016年APC -4.3%;95% CI,-4.8%至-3.8%)和胃癌(2011-2016年APC -4.4%;95% CI,-5.8%至-2.9%)中下降。
- 提供医疗服务价格和强度的增加是支出上升的最大驱动因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The management of gastrointestinal (GI) cancers is associated with high health care spending. We estimated trends in United States (US) health care spending for patients with GI cancers between 1996 and 2016 and developed projections to 2030. METHODS: We used economic data, adjusted for inflation, developed by the Institute for Health Metrics and Evaluations for the Disease Expenditure Project. Corresponding US age-adjusted prevalence of GI cancers was estimated from the Global Burden of Diseases Study. Prevalence-adjusted temporal trends in the US health care spending in patients with GI cancers, stratified by cancer site, age, and setting of care, were estimated using joinpoint regression, expressed as annual percentage change (APC) with 95% confidence intervals (CIs). Autoregressive integrated moving average models were used to project spending to 2030. RESULTS: In 2016, total spending for GI cancers was primarily attributable to colorectal ($10.50 billion; 95% CI, $9.35-$11.70 billion) and pancreatic cancer ($2.55 billion; 95% CI, $2.23-$2.82 billion), and primarily for inpatient care (64.5%). Despite increased total spending, more recent per-patient spending for pancreatic (APC 2008-2016, -1.4%; 95% CI, -2.2% to -0.7%), gallbladder/biliary tract (APC 2010-2016, -4.3%; 95% CI, -4.8% to -3.8%), and gastric cancer (APC 2011-2016, -4.4%; 95% CI, -5.8% to -2.9%) decreased. Increasing price and intensity of care provision was the largest driver of higher expenditures. By 2030, it is projected more than $21 billion annually will be spent on GI cancer management. CONCLUSIONS: Total spending for GI cancers in the US is substantial and projected to increase. Expenditures are primarily driven by inpatient care for colorectal cancer, although per-capita spending trends differ by GI cancer type.
引用
- Stukalin I, Ahmed NS, Fundytus AM, et al. Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030). Gastroenterology. 2021. PMID: 34922947. doi:10.1053/j.gastro.2021.12.244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。